MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival

Simona Rossi, Masayoshi Shimizu, Elisa Barbarotto, Milena S. Nicoloso, Federica Dimitri, Deepa Sampath, Muller Fabbri, Susan Lerner, Lynn L. Barron, Laura Z. Rassenti, Li Jiang, Lianchun Xiao, Jianhua Hu, Paola Secchiero, Giorgio Zauli, Stefano Volinia, Massimo Negrini, William Wierda, Thomas J. Kipps, William PlunkettKevin R. Coombes, Lynne V. Abruzzo, Michael J. Keating, George A. Calin

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

Aberrant expression of microRNAs (miRNAs) has been associated with clinical outcome in patients with chronic lymphocytic leukemia (CLL). To identify a powerful and easily assessable miRNA bio-marker of prognosis and survival, we performed quantitative reverse-transcription polymerase chain reaction (qRT-PCR) profiling in 104 CLL patients with a well-defined chromosome 17p status, and we validated our findings with miRNA microarray data from an independent cohort of 80 patients. We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was downregulated in therapy-refractory cases. miR-21 expression levels were significantly higher in patients with poor prognosis and predicted overall survival (OS), and miR-181b expression levels significantly predicted treatment-free survival. We developed a 21FK score (miR-21 qRT-PCR, fluorescence in situ hybridization, Karyotype) to stratify patients according to OS and found that patients with a low score had a significantly longer OS time. When we evaluated the relative power of the 21FK score with the most used prognostic factors, the score was the most significant in both CLL cohorts. We conclude that the 21FK score represents a useful tool for distinguishing between good-prognosis and poor-prognosis CLL patients.

Original languageEnglish
Pages (from-to)945-952
Number of pages8
JournalBlood
Volume116
Issue number6
DOIs
Publication statusPublished - Aug 12 2010

Fingerprint

Chromosome Deletion
B-Cell Chronic Lymphocytic Leukemia
Chromosomes
MicroRNAs
Polymerase chain reaction
Transcription
Survival
Microarrays
Refractory materials
Karyotype
Reverse Transcription
Fluorescence
Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Down-Regulation
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Rossi, S., Shimizu, M., Barbarotto, E., Nicoloso, M. S., Dimitri, F., Sampath, D., ... Calin, G. A. (2010). MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood, 116(6), 945-952. https://doi.org/10.1182/blood-2010-01-263889

MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. / Rossi, Simona; Shimizu, Masayoshi; Barbarotto, Elisa; Nicoloso, Milena S.; Dimitri, Federica; Sampath, Deepa; Fabbri, Muller; Lerner, Susan; Barron, Lynn L.; Rassenti, Laura Z.; Jiang, Li; Xiao, Lianchun; Hu, Jianhua; Secchiero, Paola; Zauli, Giorgio; Volinia, Stefano; Negrini, Massimo; Wierda, William; Kipps, Thomas J.; Plunkett, William; Coombes, Kevin R.; Abruzzo, Lynne V.; Keating, Michael J.; Calin, George A.

In: Blood, Vol. 116, No. 6, 12.08.2010, p. 945-952.

Research output: Contribution to journalArticle

Rossi, S, Shimizu, M, Barbarotto, E, Nicoloso, MS, Dimitri, F, Sampath, D, Fabbri, M, Lerner, S, Barron, LL, Rassenti, LZ, Jiang, L, Xiao, L, Hu, J, Secchiero, P, Zauli, G, Volinia, S, Negrini, M, Wierda, W, Kipps, TJ, Plunkett, W, Coombes, KR, Abruzzo, LV, Keating, MJ & Calin, GA 2010, 'MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival', Blood, vol. 116, no. 6, pp. 945-952. https://doi.org/10.1182/blood-2010-01-263889
Rossi, Simona ; Shimizu, Masayoshi ; Barbarotto, Elisa ; Nicoloso, Milena S. ; Dimitri, Federica ; Sampath, Deepa ; Fabbri, Muller ; Lerner, Susan ; Barron, Lynn L. ; Rassenti, Laura Z. ; Jiang, Li ; Xiao, Lianchun ; Hu, Jianhua ; Secchiero, Paola ; Zauli, Giorgio ; Volinia, Stefano ; Negrini, Massimo ; Wierda, William ; Kipps, Thomas J. ; Plunkett, William ; Coombes, Kevin R. ; Abruzzo, Lynne V. ; Keating, Michael J. ; Calin, George A. / MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. In: Blood. 2010 ; Vol. 116, No. 6. pp. 945-952.
@article{15390a4bfc0b4ea09261e889053f0541,
title = "MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival",
abstract = "Aberrant expression of microRNAs (miRNAs) has been associated with clinical outcome in patients with chronic lymphocytic leukemia (CLL). To identify a powerful and easily assessable miRNA bio-marker of prognosis and survival, we performed quantitative reverse-transcription polymerase chain reaction (qRT-PCR) profiling in 104 CLL patients with a well-defined chromosome 17p status, and we validated our findings with miRNA microarray data from an independent cohort of 80 patients. We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was downregulated in therapy-refractory cases. miR-21 expression levels were significantly higher in patients with poor prognosis and predicted overall survival (OS), and miR-181b expression levels significantly predicted treatment-free survival. We developed a 21FK score (miR-21 qRT-PCR, fluorescence in situ hybridization, Karyotype) to stratify patients according to OS and found that patients with a low score had a significantly longer OS time. When we evaluated the relative power of the 21FK score with the most used prognostic factors, the score was the most significant in both CLL cohorts. We conclude that the 21FK score represents a useful tool for distinguishing between good-prognosis and poor-prognosis CLL patients.",
author = "Simona Rossi and Masayoshi Shimizu and Elisa Barbarotto and Nicoloso, {Milena S.} and Federica Dimitri and Deepa Sampath and Muller Fabbri and Susan Lerner and Barron, {Lynn L.} and Rassenti, {Laura Z.} and Li Jiang and Lianchun Xiao and Jianhua Hu and Paola Secchiero and Giorgio Zauli and Stefano Volinia and Massimo Negrini and William Wierda and Kipps, {Thomas J.} and William Plunkett and Coombes, {Kevin R.} and Abruzzo, {Lynne V.} and Keating, {Michael J.} and Calin, {George A.}",
year = "2010",
month = "8",
day = "12",
doi = "10.1182/blood-2010-01-263889",
language = "English",
volume = "116",
pages = "945--952",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - MicroRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival

AU - Rossi, Simona

AU - Shimizu, Masayoshi

AU - Barbarotto, Elisa

AU - Nicoloso, Milena S.

AU - Dimitri, Federica

AU - Sampath, Deepa

AU - Fabbri, Muller

AU - Lerner, Susan

AU - Barron, Lynn L.

AU - Rassenti, Laura Z.

AU - Jiang, Li

AU - Xiao, Lianchun

AU - Hu, Jianhua

AU - Secchiero, Paola

AU - Zauli, Giorgio

AU - Volinia, Stefano

AU - Negrini, Massimo

AU - Wierda, William

AU - Kipps, Thomas J.

AU - Plunkett, William

AU - Coombes, Kevin R.

AU - Abruzzo, Lynne V.

AU - Keating, Michael J.

AU - Calin, George A.

PY - 2010/8/12

Y1 - 2010/8/12

N2 - Aberrant expression of microRNAs (miRNAs) has been associated with clinical outcome in patients with chronic lymphocytic leukemia (CLL). To identify a powerful and easily assessable miRNA bio-marker of prognosis and survival, we performed quantitative reverse-transcription polymerase chain reaction (qRT-PCR) profiling in 104 CLL patients with a well-defined chromosome 17p status, and we validated our findings with miRNA microarray data from an independent cohort of 80 patients. We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was downregulated in therapy-refractory cases. miR-21 expression levels were significantly higher in patients with poor prognosis and predicted overall survival (OS), and miR-181b expression levels significantly predicted treatment-free survival. We developed a 21FK score (miR-21 qRT-PCR, fluorescence in situ hybridization, Karyotype) to stratify patients according to OS and found that patients with a low score had a significantly longer OS time. When we evaluated the relative power of the 21FK score with the most used prognostic factors, the score was the most significant in both CLL cohorts. We conclude that the 21FK score represents a useful tool for distinguishing between good-prognosis and poor-prognosis CLL patients.

AB - Aberrant expression of microRNAs (miRNAs) has been associated with clinical outcome in patients with chronic lymphocytic leukemia (CLL). To identify a powerful and easily assessable miRNA bio-marker of prognosis and survival, we performed quantitative reverse-transcription polymerase chain reaction (qRT-PCR) profiling in 104 CLL patients with a well-defined chromosome 17p status, and we validated our findings with miRNA microarray data from an independent cohort of 80 patients. We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was downregulated in therapy-refractory cases. miR-21 expression levels were significantly higher in patients with poor prognosis and predicted overall survival (OS), and miR-181b expression levels significantly predicted treatment-free survival. We developed a 21FK score (miR-21 qRT-PCR, fluorescence in situ hybridization, Karyotype) to stratify patients according to OS and found that patients with a low score had a significantly longer OS time. When we evaluated the relative power of the 21FK score with the most used prognostic factors, the score was the most significant in both CLL cohorts. We conclude that the 21FK score represents a useful tool for distinguishing between good-prognosis and poor-prognosis CLL patients.

UR - http://www.scopus.com/inward/record.url?scp=77956556260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956556260&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-01-263889

DO - 10.1182/blood-2010-01-263889

M3 - Article

C2 - 20393129

AN - SCOPUS:77956556260

VL - 116

SP - 945

EP - 952

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -